Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Analgesic Efficacy and Safety Study of Naproxcinod in Subjects With Osteoarthritis of the Knee.

Next Previous
X
Search
Trial Profile

Analgesic Efficacy and Safety Study of Naproxcinod in Subjects With Osteoarthritis of the Knee.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 23 Jun 2011

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Naproxcinod (Primary) ; Naproxen
  • Indications Musculoskeletal pain; Osteoarthritis
  • Focus Adverse reactions; Pharmacodynamics; Registrational; Therapeutic Use
  • Sponsors NicOx

    • Most Recent Events

    • 23 Jul 2010 FDA does not approve NDA according to a media release from NICOX.
    • 03 May 2010 Undisclosed results from a pre-specified pooled analysis of the 301, 302 and 303 naproxcinod studies were presented at ASH 2010, according to a NicOx media release. The abstract has been published in the Journal of Clinical Hypertension 2010, 12 (s1), A5.
    • 01 May 2010 Prespecified pooled pharmacodynamic analysis presented at the 25th Annual Scientific Meeting of the American Society of Hypertension.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top